SKB410 / Sichuan Kelun Pharma, Merck (MSD) - LARVOL DELTA

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov) - P1/2 | N=180 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1/2 trial • Oncology • Solid Tumor

SKB410 for Injection in Solid Tumors (clinicaltrials.gov) - P1 | N=276 | Active, not recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

SKB410 for Injection in Solid Tumors (clinicaltrials.gov) - P1 | N=276 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Kelun-Biotech Announces Interim Results for 2023 (Yahoo Finance) - "Kelun-Biotech’s core product, SKB264, was granted a Breakthrough Therapy Designation (BTD) in January, 2023 by the National Medical Products Administration (NMPA) for EGFR-TKI failed EGFR-mutant locally advanced or metastatic NSCLC and another BTD in June for locally advanced or metastatic hormone receptor positive (HR)+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) which has previously received at least 2L systemic chemotherapy...The phase Ia clinical trials of SKB410 for advanced solid tumors, which also received IND approval from the NMPA, successfully enrolled the first patient in July 2023."

Breakthrough therapy designation • Non-US regulatory • Trial status • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

SKB410 for Injection in Solid Tumors (clinicaltrials.gov) - P1 | N=276 | Not yet recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor